Basic Information
| LncRNA/CircRNA Name | LINC01314 |
| Synonyms | DUXAP9, LINC01296, FLJ39632, lncRNA-CTD903 |
| Region | GRCh38_14:19062316-19131167 |
| Ensemble | ENSG00000225210 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatoblastoma |
| ICD-0-3 | C22.0 |
| Methods | Microarray, Western blot |
| Sample | HB liver tissues |
| Expression Pattern | down-regulated |
| Function Description | Our results showed decreased proliferation and migration activities of HB cells overexpressing LINC01314. Moreover, mechanistic investigations revealed that LINC01314 overexpression inhibited nuclear translocation of YAP, by inducing MST1 expression and promoting phosphorylation of LATS1 and YAP, consequently downregulating the expression of cell cycle regulatory proteins (MCM7 and cyclin D1). |
| Pubmed ID | 29571247 |
| Year | 2018 |
| Title | Comprehensive analysis and experimental verification of LINC01314 as a tumor suppressor in hepatoblastoma. |
External Links
| Links for LINC01314 | GenBank HGNC NONCODE |
| Links for hepatoblastoma | OMIM COSMIC |